The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Open accessAbstract
Chimeric antigen receptor (CAR) T cells have been highly successful in treating hematological malignancies, including acute and chronic lymphoblastic leukemia. However, treatment of solid tumors using CAR T cells has been largely unsuccessful to date, partly because of tumor-induced immunosuppressive mechanisms, including adenosine production. Previous studies have shown that adenosine generated by tumor cells potently inhibits endogenous antitumor T cell responses through activation of adenosine 2A receptors (A2ARs). Herein, we have observed that CAR activation resulted in increased A2AR expression and suppression of both murine and human CAR T cells. This was reversible using either A2AR antagonists or genetic targeting of A2AR using shRNA. In 2 syngeneic HER2+ self-antigen tumor models, we found that either genetic or pharmacological targeting of the A2AR profoundly increased CAR T cell efficacy, particularly when combined with PD-1 blockade. Mechanistically, this was associated with increased cytokine production of CD8+ CAR T cells and increased activation of both CD8+ and CD4+ CAR T cells. Given the known clinical relevance of the CD73/adenosine pathway in several solid tumor types, and the initiation of phase I trials for A2AR antagonists in oncology, this approach has high translational potential to enhance CAR T cell efficacy in several cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Self-citationImmunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Structure and function of adenosine receptors and their genes
Fredholm, B. B., Arslan, G., Halldner, L., Kull, B., Schulte, G., & Wasserman, W. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000313 · Cited by 583
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Self-citationAdusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 523
Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Self-citationCD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Self-citationTargeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458
Self-citationJin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 432
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
A2A Adenosine Receptor Induction Inhibits IFN-γ Production in Murine CD4+ T Cells
Lappas, C. M., Rieger, J. M., & Linden, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.1073 · Cited by 385
CD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 355
Self-citationBlockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
Self-citationBeavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0211 · Cited by 334
Self-citationCekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Self-citationCD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
Turcotte, M., Spring, K., Pommey, S., Chouinard, G., Cousineau, I., George, J., Chen, G. M., Gendoo, D. M. A., Haibe-Kains, B., Karn, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3569 · Cited by 257
Self-citationSitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253
Cutting Edge: Critical Role for A2A Adenosine Receptors in the T Cell-Mediated Regulation of Colitis
Naganuma, M., Wiznerowicz, E. B., Lappas, C. M., Linden, J., Worthington, M. T., & Ernst, P. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.2765 · Cited by 240
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Leone, R. D., Lo, Y.-C., & Powell, J. D. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.03.008 · Cited by 225
Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Johnstone, C. N., Smith, Y. E., Cao, Y., Burrows, A. D., Cross, R. S. N., Ling, X., Redvers, R. P., Doherty, J. P., Eckhardt, B. L., Natoli, A. L., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017830 · Cited by 207
Self-citationCD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
Leclerc, B. G., Charlebois, R., Chouinard, G., Allard, B., Pommey, S., Saad, F., & Stagg, J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1181 · Cited by 200
Self-citationGao, Z.-W., Dong, K., & Zhang, H.-Z. (2014) · BioMed Research International · doi:10.1155/2014/460654 · Cited by 195
Suppression of LPS-Induced TNF-α Production in Macrophages by cAMP Is Mediated by PKA-AKAP95-p105
Wall, E. A., Zavzavadjian, J. R., Chang, M. S., Randhawa, B., Zhu, X., Hsueh, R. C., Liu, J., Driver, A., Bao, X. R., Sternweis, P. C., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000202 · Cited by 188
Quattrocchi, K. B., Miller, C. H., Cush, S., Bernard, S. A., Dull, S. T., Smith, M., Gudeman, S., & Varia, M. A. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006293606710 · Cited by 168
Tammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R., & Zhou, X. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.122 · Cited by 165
Figlin, R. A., Pierce, W. C., Kaboo, R., Tso, C. L., Moldawer, N., Gitlitz, B., deKernion, J., & Belldegrun, A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64304-0 · Cited by 160
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
Waickman, A. T., Alme, A., Senaldi, L., Zarek, P. E., Horton, M. R., & Powell, J. D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1155-7 · Cited by 155
Westwood, J. A., Smyth, M. J., Teng, M. W. L., Moeller, M., Trapani, J. A., Scott, A. M., Smyth, F. E., Cartwright, G. A., Power, B. E., Hönemann, D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504312102 · Cited by 148
Self-citationHaynes, N. M., Snook, M. B., Trapani, J. A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.182 · Cited by 139
Self-citationHauser, R. A., Olanow, C. W., Kieburtz, K. D., Pourcher, E., Axelerad, A. D., Lew, M., Kozyolkin, О. А., Neale, A. C., Resburg, C., Meya, U., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70148-6 · Cited by 132
Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2014) · Europe PMC (PubMed Central) · Cited by 129
Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 127
Moeller, M., Haynes, N. M., Kershaw, M. H., Jackson, J. T., Teng, M. W. L., Street, S. E. A., Cerruti, L., Jane, S. M., Trapani, J. A., Smyth, M. J., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4906 · Cited by 122
Self-citationShi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications · doi:10.1038/ncomms12335 · Cited by 111
Häusler, S. F., del Barrio, I. M., Diessner, J., Stein, R. G., Strohschein, J., Hönig, A., Dietl, J., & Wischhusen, J. (2014) · Europe PMC (PubMed Central) · Cited by 109
Chapuis, A. G., Lee, S. M., Thompson, J. A., Roberts, I. M., Margolin, K. A., Bhatia, S., Sloan, H. L., Lai, I. P., Wagener, F. D., Shibuya, K. C., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20152021 · Cited by 89
Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer
Kershaw, M. H., Jackson, J. T., Haynes, N. M., Teng, M. W. L., Moeller, M., Hayakawa, Y., Street, S. E. A., Cameron, R., Tanner, J. E., Trapani, J. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2143 · Cited by 83
Self-citationRedirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL
Darcy, P. K., Haynes, N. M., Snook, M. B., Trapani, J. A., Cerruti, L., Jane, S. M., & Smyth, M. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3705 · Cited by 83
Self-citationReprogramming the tumor microenvironment to enhance adoptive cellular therapy
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Gyorki, D. E., Neeson, P. J., & Darcy, P. K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.003 · Cited by 79
Self-citationCD73: A potential biomarker for anti-PD-1 therapy
Beavis, P. A., Slaney, C. Y., Milenkovski, N., Henderson, M. A., Loi, S., Stagg, J., Kershaw, M. H., & Darcy, P. K. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046675 · Cited by 41
Self-citationHigh expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma
Zhang, B., Cheng, B., Li, F., Ding, J., Feng, Y., Zhuo, G., Wei, H., & Zhao, K. (2015) · Tumor Biology · doi:10.1007/s13277-015-3683-9 · Cited by 40
Shiloni, E., Karp, S. E., Custer, M. C., Shilyansky, J., Restifo, N. P., Rosenberg, S. A., & Mul, J. J. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01518450 · Cited by 27
Enhancing the Efficacy of Adoptive Cellular Therapy By Targeting Tumor-InDuced Immunosuppression
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Neeson, P. J., & Darcy, P. K. (2015) · Immunotherapy · doi:10.2217/imt.15.16 · Cited by 18
Self-citationPackaging shRNA RetrovirusesPreprint
Chang, K., Marran, K., Valentine, A., & Hannon, G. J. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot076448 · Cited by 16
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Metadata
- Authors
- Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., Johnstone, R. W., Trapani, J. A., Stagg, J., Loi, S., Kats, L., Gyorki, D., Kershaw, M. H., & Darcy, P. K.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-02-06
- Volume
- 127
- Issue
- 3
- Pages
- 929-941
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2584913109
- Cited by
- 325
- References
- 64
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.